Trial reportJournal of acquired immune deficiency syndromes (1999)2013
CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy.
Trial report in Journal of acquired immune deficiency syndromes (1999), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- Pre-Human Immunodeficiency Virus (HIV) infection Th17 CD4+ T cells as predictors of early HIV disease progression.PLoS pathogens · 2026Article
- A Guide to the Evolving Clinical Landscape of Low-Level Viremia Among Persons with HIV in the Modern Treatment Era.Current HIV/AIDS reports · 2025Review
- Pre-Human Immunodeficiency Virus (HIV) α4β7hi CD4+ T Cells and HIV Risk Among Heterosexual Individuals in Africa.The Journal of infectious diseases · 2025Article
- Risk Factors Associated with Virological Failure in HIV Patients with Low Level Viremia: A Retrospective Study.Infection and drug resistance · 2025Article
- Article
- Transient Viral Rebound in Children with Perinatally Acquired HIV-1 Induces a Unique Soluble Immunometabolic Signature Associated with Decreased CD4/CD8 Ratio.Journal of the Pediatric Infectious Diseases Society · 2023Article
- HIV-1 viral blips are associated with repeated and increasingly high levels of cell-associated HIV-1 RNA transcriptional activity.AIDS (London, England) · 2021Article
- The role of CD38 in HIV infection.AIDS research and therapy · 2021Review
- Persistent Low-Level Viremia is an Independent Risk Factor for Virologic Failure: A Retrospective Cohort Study in China.Infection and drug resistance · 2021Article
- Patterns of detectable viraemia among children and adults with HIV infection taking antiretroviral therapy in Zimbabwe.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2019Article
- Is weak CD4+ gain in the course of suppressive combination antiretroviral therapy for HIV infection a current clinical challenge? A case report and brief review of the literature.BMC infectious diseases · 2018Review
- Polymorphisms in the CD14 and TLR4 genes independently predict CD4+ T-cell recovery in HIV-infected individuals on antiretroviral therapy.AIDS (London, England) · 2016Article
- Latent and Active Tuberculosis Infection Increase Immune Activation in Individuals Co-Infected with HIV.EBioMedicine · 2015Article
- Potential implication of residual viremia in patients on effective antiretroviral therapy.AIDS research and human retroviruses · 2015Review
- Factors associated with CD8+ T-cell activation in HIV-1-infected patients on long-term antiretroviral therapy.Journal of acquired immune deficiency syndromes (1999) · 2014Observational
- Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients.Antimicrobial agents and chemotherapy · 2014Article
- Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014Article
- Residual viremia is preceding viral blips and persistent low-level viremia in treated HIV-1 patients.PloS one · 2014Article
- Altering cell death pathways as an approach to cure HIV infection.Cell death & disease · 2013Review
- Immune activation and HIV persistence: implications for curative approaches to HIV infection.Immunological reviews · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 1 country.
Funding
Abstract
Transient low-level viremia (TLLV) of 50-400 HIV RNA copies per milliliter is common during antiretroviral therapy, but its pathogenesis, consequences, and optimal management are unclear. Heightened immune activation is associated with detrimental outcomes, including impaired CD4 T-cell reconstitution. Using CD38/HLA-DR expression on CD8 T cells measured in 2 large studies, we determined associations between TLLV and immune activation levels before, during, and after TLLV. We found that TLLV does not significantly change CD8 T-cell activation and that higher CD8 T-cell activation during viral suppression <50 copies per milliliter is associated with a modest increase in the risk of a subsequent TLLV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.